Hematopoiesis News Volume 13.19 | May 17 2022

    By
    Britya Ghosh
    -
    0
    30






    2022-05-17 | HN 13.18


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.19 – 17 May, 2022
    TOP STORY

    Epigenetic Traits Inscribed in Chromatin Accessibility in Aged Hematopoietic Stem Cells

    Scientists presented an integrated analysis of transcriptome and chromatin accessibility of aged HSCs and downstream progenitors.
    [Nature Communications]

    Full Article

    Virtual Conference Exhibition: Pluripotent Stem Cells
    PUBLICATIONSRanked by the impact factor of the journal

    Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia

    Researchers indicated that acute lymphoblastic leukemia risk variants in ARID5B functioned by modulating cis-regulatory elements at this locus.
    [JNCI-Journal of the National Cancer institute]

    Abstract

    Chemically-Defined Generation of Human Hemogenic Endothelium and Definitive Hematopoietic Progenitor Cells

    Scientists showed that temporal manipulation of Wnt signaling was sufficient and essential to induce aorta-gonad-mesonephros-like hematopoiesis from human pluripotent stem cells.
    [Biomaterials]

    Full Article

    CD1d Expression Demarcates CDX4+ Hemogenic Mesoderm with Definitive Hematopoietic Potential

    Researchers reported that early mesodermal expression of CDX4 critically regulates definitive hemogenic endothelium specification, suggesting that CDX4 might act in a cell-autonomous manner during hematopoietic development.
    [Stem Cell Research]

    Full Article

    Hirsutine, a Novel Megakaryopoiesis Inducer, Promotes Thrombopoiesis via MEK/ERK/FOG1/TAL1 Signaling

    The authors aimed to identify more effective active compounds for thrombocytopenia therapy.
    [Phytomedicine]

    AbstractGraphical Abstract

    Generation and Clinical Potential of Functional T Lymphocytes from Gene-Edited Pluripotent Stem Cells

    Single-cell transcriptome analysis of PSC-derived induced hematopoietic stem and progenitor cells (iHSPC)/induced T cells identified the developmental pathways and possibilities of generating functional T cell from PSCs.
    [Experimental Hematology & Oncology]

    Full Article

    Co-Variates Associated with Outcomes of Tyrosine Kinase-Inhibitor Therapy in Persons with Chronic Myeloid Leukemia Initially Presenting in Accelerated Phase

    The authors interrogated data from 278 consecutive subjects with chronic myeloid leukaemia presenting in accelerated phase diagnosed by European LeukemiaNet criteria receiving initial imatinib or a second-generation tyrosine kinase-inhibitor.
    [Leukemia]

    Abstract

    Comparison of Fludarabine–Melphalan and Fludarabine–Treosulfan as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation—a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

    Scientists compared outcome after two frequently used single alkylator-based conditioning protocols from the intermediate transplantation conditioning intensity score category, fludarabine/melphalan 140 mg/m2 and fludarabine/treosulfan 42 g/m2 for patients with acute myeloid leukemia in complete remission.
    [Bone Marrow Transplantation]

    Full Article

    Autologous Hematopoietic Stem Cell Transplantation Followed by Interleukin-2 for Adult Acute Myeloid Leukemia Patients with Favorable or Intermediate Risk after Complete Remission

    The authors conducted a retrospective study on the long-term outcome of acute myeloid leukemia patients with favorable or intermediate risk who underwent autologous hematopoietic stem cell transplantation followed by interleukin-2 subcutaneous injection as maintenance therapy.
    [Annals of Hematology]

    Abstract

    Request your free copy of the 'Frequencies of Cell Types in Human Peripheral Blood' Wallchart
    REVIEWS

    Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases: Overview and Future Considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)

    Scientists describe the interwoven challenges of delivering more advanced cellular therapies, exploiting mesenchymal stem cells, regulatory T cells and potentially CAR-T cell therapies, in patients affected by autoimmune diseases.
    [Bone Marrow Transplantation]

    Full Article

    INDUSTRY AND POLICY NEWS

    Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

    Jasper Therapeutics, Inc. announced the dosing of the first patient in the Company’s sponsored research of the Center for Definitive and Curative Medicine at the Stanford University School of Medicine for the study of JPS191 as a conditioning agent in the treatment of Fanconi Anemia.
    [Jasper Therapeutics, Inc. (GlobeNewswire, Inc.)]

    Press Release

    FEATURED EVENT

    European Association for Cancer Research (EACR) 2022: Innovative Cancer Science

    June 20 – 23, 2022
    Seville, Spain

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Breast Cancer and Leukemia

    Duke University – Durham, North Carolina, United States

    Postdoctoral Researcher – Microfluidics

    Flanders Institute for Biotechnology – Leuven, Belgium

    Research Scientist – Service Development

    NHS Blood and Transplant – London, England, United Kingdom

    Postdoctoral Fellow – Disease Modeling

    University Children’s Hospital – Zurich, Germany

    Postdoctoral Researcher – Leukemia Subtypes

    University Children’s Hospital of Zurich – Zurich, Switzerland

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter